Clinical trial
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV…
NCT00323544 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00323544 |
|---|---|
| Title | SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection |
| Official title | A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Twice Daily co-Formulated Zidovudine and… |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | zidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF |
| Enrollment | 220 |
| Start date | Oct 1, 2004 |
| Primary completion | Jun 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | May 9, 2006 |
| Last update posted | Jul 4, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: